Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to establish that an optimal dose of Quillivant XR oral
suspension would result in a significant reduction in signs and symptoms of ADHD compared to
placebo treatment in pediatric patients ages 6-12 years with ADHD.